Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Transparency Rule

18th Dec 2006 16:01

PuriCore Plc18 December 2006 18 December 2006 PuriCore plc Total Voting Rights and Share Capital In conformity with the Transparency Directive's transitional provision 6,PuriCore plc is required to notify the market of the following: PuriCore plc's issued share capital consists of 151,888,792 ordinary shares witha nominal value of 1 pence each, with voting rights. PuriCore plc does not holdany ordinary shares in Treasury. Therefore, the total number of voting rights in PuriCore plc is 151,888,792. The above figure of 151,888,792 shares may be used by shareholders as thedenominator for the calculations by which they will determine if they arerequired to notify their interest in, or a change to their interest in, PuriCoreplc under the Financial Service Authority's Disclosure and Transparency Rules. Name of contact and telephone number for enquiries: Keith Goldan+001 484 321 2700Chief Financial Officer PuriCore plc58 Davies StreetLondonW1K 5JF Tel: +001 484 321 2700www.puricore.com Registered in England and Wales No. 5789798 ABOUT PURICORE PLC PuriCore is a life sciences company focused on the development andcommercialization of its proprietary technology that mimics the production bythe human body of its natural anti-microbial, hypochlorous acid. Hypochlorousacid is highly effective at killing pathogens such as bacteria, viruses andfungi and yet is safe and environmentally friendly. PuriCore's solutions haveapplications in a wide range of markets where it is important to controlmicrobial contamination. These markets include medical device disinfection,food safety, dental equipment decontamination, environmental remediation,hospitality, water safety, wound management and other applications intended tolimit the spread of infectious disease, including major global threats such asTuberculosis, MRSA, Influenza, E.coli, Norovirus, HIV, polio, Hepatitis A,H.pylori and Legionella. PuriCore markets a portfolio of branded systems which produce hypochlorous acidsolutions on-site at a customer's location from water, electricity and commonsalt. These solutions are generated at a range of concentrations and at anearly neutral pH range similar to the human body. They are effective as soaks,sprays, mists and in other forms. PuriCore is headquartered in Malvern, Pennsylvania and has offices in Stafford,UK. To receive additional information on the Company, please visit our Web site atwww.puricore.com, which does not form part of this press release. This information is provided by RNS The company news service from the London Stock Exchange

Related Shares:

RLM.L
FTSE 100 Latest
Value8,275.66
Change0.00